FDA Approved Indications for this Orphan Drug:

Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.

FDA Marketing Approval issued as of:
05/17/1996

Orphan Drug exclusivity ends on:
05/17/2003
Company Making and Marketing this drug:
Catalytica Pharmaceuticals, Inc

FDA Designation Date:
10/16/92

FDA Drug Designation:
Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.